Montreal, QC – February 1, 2010 – Canadian families managing Attention Deficit Hyperactivity Disorder (ADHD) have a new treatment option. Canadian families managing Attention Deficit Hyperactivity Disorder (ADHD) have a new treatment option. Today, Shire plc, the global specialty biopharmaceutical company, announced the Canadian availability of VYVANSE (lisdexamfetamine dimesylate capsule), the first and only prodrug therapy approved for ADHD treatment in Canada.